CD47 and neoplasm: A classic example in cancer is bispecific antibodies targeting CD47 and tumor‐associated antigens such as CD20358 and PD‐L1359 that specifically target macrophages in tumor site, promoting phagocytosis of tumor cells by macrophages but sparing the host cells that do not express the tumor antigens such as platelets and red blood cells, showing limited toxicity.